ArriVent BioPharma, Inc. AVBP Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| $45.54M-38.7% | $74.29M-50.6% | $150.39M— | ||
| $267.28M+84.9% | $144.57M— | —— | ||
| $332.9M+46.7% | $226.98M+41.9% | $159.97M— | ||
| $333.17M+21.2% | $274.94M+68.6% | $163.1M— | ||
| $5.93M+56.9% | $3.78M-16.5% | $4.53M— | ||
| $25.95M+50.2% | $17.27M+48.6% | $11.62M— | ||
| $25.95M+50.1% | $17.29M+46.5% | $11.8M— | ||
| $4K+33.3% | $3K— | —— | ||
| -$404.64M-69.8% | -$238.33M-51.0% | -$157.85M— | ||
| $307.22M+19.2% | $257.65M+268% | -$153.19M-80.0% | ||
| $333.17M+21.2% | $274.94M+68.6% | $163.1M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can ArriVent BioPharma, Inc. cover its short-term obligations?
- Its current ratio is 13.95 — current assets exceed current liabilities.
- Where does ArriVent BioPharma, Inc.'s balance sheet data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.